Xcout Intel
Ensho Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Ensho Therapeutics, Inc. among drug discovery companies — ranked by similarity to what Ensho Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Ensho Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Ensho Therapeutics, Inc.
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients. Founded in 2024, the company is based in Morris Plains, New Jersey.
Ensho Therapeutics, Inc. at a glance
Ensho Therapeutics, Inc. is a drug discovery company headquartered in United States. Its most recent funding round raised $20M in January 2026. Xcout tracks 19 named people at Ensho Therapeutics, Inc., including Gerhard Hagn (Chief Executive Officer).
Ensho Therapeutics, Inc. leadership
- Gerhard HagnChief Executive Officer
- Neena Bitritto-GargPresident and CEO
- Danielle FryChief Operating Officer and Chief Legal Officer
- Andy WhitneyChief Scientific Officer
- Tory TrippeVice President, Head of Finance and Corporate Development
- Bittoo KanwarExecutive Officer
13 more named people on record for Ensho Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Ensho Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — | |
| SEC Form D filing | $22.5M | — | |
| Debt | $5M | — | |
| SEC Form D filing | $400,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Ensho Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Ensho Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
KayoThera, Inc. is an early-stage, preclinical therapeutics company headquartered in Seattle, Washington. The firm focuses on developing first-in-class, oral, small molecule treatments.
Similar drug discovery company
Promontory Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company founded in 2010 and headquartered in New York, NY. The firm focuses on small molecule immunotherapy.
Similar drug discovery company
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Similar drug discovery company
Momotaro-Gene Inc. is a drug discovery company established in 2007 and headquartered in Okayama, Japan. The company focuses on pharmaceutical research and the development of next-generation cancer therapeutics.
Similar drug discovery company
Aneira Pharma, Inc. is a privately held pharmaceutical company founded in 2008 with its headquarters in San Diego, California.
Biopharma
Engrail Therapeutics, Inc. is a clinical-stage neurosciences and pharmaceutical company established in 2019 and headquartered in San Diego, California. The firm focuses on developing novel treatments such as its planned ENX-104 clinical program.
Biopharmaceutical
Eilean Therapeutics is an oncology drug discovery company focused on developing small-molecule treatments to combat cancer drug resistance. The company advances targeted therapies, such as selective JAK2 inhibitors, into first-in-human clinical development. Their research pipeline is dedicated to creating pan-variant treatments for challenging hematologic malignancies.
Biopharmaceuticals
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Biopharmaceutical
Eddingpharm is a specialty pharmaceutical company headquartered in Shanghai, China, operating within the rapidly growing domestic healthcare market. The company focuses on the development, acquisition, and commercialization of innovative pharmaceutical products across multiple therapeutic areas. Formerly venture-backed, it functions as a prominent publicly held healthcare entity in the region.
Biopharmaceuticals
JDP Therapeutics, Inc. is a pharmaceutical company with its operations and headquarters located in Lansdale, Pennsylvania, focusing on the development of specialty therapeutics.
Biopharmaceuticals
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Oncology
Avenzo Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing next-generation oncology treatments.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Ensho Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Ensho Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →